927 Shares in Cencora, Inc. (NYSE:COR) Purchased by Tower Wealth Partners Inc.

Tower Wealth Partners Inc. bought a new stake in shares of Cencora, Inc. (NYSE:COR) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 927 shares of the company’s stock, valued at approximately $209,000.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. purchased a new stake in shares of Cencora during the 4th quarter worth $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Cencora during the first quarter valued at about $2,183,619,000. JPMorgan Chase & Co. bought a new stake in shares of Cencora in the 1st quarter valued at about $1,199,695,000. Boston Partners purchased a new position in shares of Cencora in the 1st quarter worth approximately $1,001,269,000. Finally, Capital Research Global Investors bought a new position in shares of Cencora during the 1st quarter worth approximately $650,424,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Wells Fargo & Company raised their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. raised their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Leerink Partners reissued an “outperform” rating and issued a $275.00 price target on shares of Cencora in a report on Thursday, June 27th. Finally, Robert W. Baird cut their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $258.13.

Insider Buying and Selling at Cencora

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. Insiders own 15.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $241.24 on Tuesday. Cencora, Inc. has a 52 week low of $177.00 and a 52 week high of $247.66. The business’s 50 day moving average price is $234.28 and its 200 day moving average price is $233.28. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The firm has a market cap of $48.12 billion, a P/E ratio of 26.39, a P/E/G ratio of 1.55 and a beta of 0.44.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating the consensus estimate of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.92 EPS. On average, sell-side analysts expect that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 0.85%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio is currently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.